- Advertisement -
- Advertisement -
- Advertisement -

Find a job

Subscribe for free

All things Pharma

Genetic link between inflammatory bowel disease and Parkinson’s disease

A genetic link between inflammatory bowel disease (IBD) and Parkinson’s disease (PD) has been identified by researchers at the Icahn School of Medicine, Mount Sinai.

The team used advanced genomic analysis techniques to investigate the genetic overlap between IBD and PD, with their findings pointing to mutations in the LRRK2 gene as a common element linking both conditions, also identifying novel genes that are likely to be affected in people experiencing both IBD and PD.

The study analysed data from the Mount Sinai BioMe BioBank, the UK Biobank, and a cohort of 67 patients diagnosed with both IBD and PD from the Danish National Biobank. This combined dataset enabled the researchers to explore high-impact rare genetic variants and identify new genes and biological pathways that contribute to the IBD-PD comorbidity.

Researchers used a variety of computational methods to uncover significant associations between the LRRK2 gene variants and the co-occurrence of IBD and PD, including the network-based heterogeneity clustering approach, which they have demonstrated to be highly effective for gene discoveries in small cohorts that cannot be analysed by traditional gene association methods. Their analysis also revealed several pathways related to immunity, inflammation, and autophagy, the body’s cellular recycling system, that are involved in both conditions.

These insights have potential implications across multiple areas of medicine, suggesting that understanding genetic factors could lead to better-targeted therapies.

The study underscores the importance of genetic research in developing personalised medicine approaches that could improve treatment for patients with both IBD and PD.

The results of this study could also influence future research directions, encouraging a more integrated approach to studying diseases that may appear unrelated but share common genetic pathways.

Dr Meltem Ece Kars, MD, PhD, from The Charles Bronfman Institute for Personalised Medicine said: “We’ve found that IBD and PD are caused by certain shared genetic factors, including variants in LRRK2 and other genes previously unknown for this combined condition. This could dramatically change our approach to these diseases, allowing for therapies that target both conditions simultaneously. Our research not only links these two diseases genetically but also sets the stage for new forms of treatment, and potentially prevention strategies, that could lessen the burden of these diseases on patients. By pinpointing the genetic underpinnings common to both IBD and PD, we pave the way for innovative treatments, whether through the development of novel drug targets or the repurposing of existing drugs, that could potentially tackle the root causes of these conditions.”

- Advertisement -
Joanna Harvey
Joanna Harvey
Marketing and Communication Executive | Uniphar Commercial


- Advertisement -



Sign up to receive our digital newsletter, for all the essential headlines, Jobs of the Week and thought-provoking features.

Claim my free subscription